Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study

Author:

Iijima Raisuke1ORCID,Tokue Masahide2ORCID,Nakamura Masato1ORCID,Yasuda Satoshi3,Kaikita Koichi4ORCID,Akao Masaharu5ORCID,Ako Junya6ORCID,Matoba Tetsuya7ORCID,Miyauchi Katsumi8ORCID,Hagiwara Nobuhisa9,Kimura Kazuo10ORCID,Hirayama Atsushi11ORCID,Matsui Kunihiko12ORCID,Ogawa Hisao13ORCID,

Affiliation:

1. Division of Cardiovascular Medicine Toho University Ohashi Medical Center Tokyo Japan

2. Kawasaki Miyamaedaira Tokue Internal‐Cardiovascular Medical Clinic Kawasaki Japan

3. Department of Cardiovascular Medicine Tohoku University Graduate School of Medicine Sendai Japan

4. Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine University of Miyazaki Miyazaki Japan

5. Department of Cardiology National Hospital Organization Kyoto Medical Center Kyoto Japan

6. Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan

7. Department of Cardiovascular Medicine, Faculty of Medical Sciences Kyushu University Fukuoka Japan

8. Department of Cardiovascular Medicine Juntendo Tokyo Koto Geriatric Medical Center Tokyo Japan

9. Department of Cardiology Tokyo Women’s Medical University Tokyo Japan

10. Department of Cardiology Yokosuka City Hospital Yokosuka Japan

11. Department of Cardiology Osaka Police Hospital Osaka Japan

12. Department of General Medicine Kumamoto University Hospital Kumamoto Japan

13. Kumamoto University Kumamoto Japan

Abstract

Background Thrombocytopenia poses a risk of bleeding in patients with chronic coronary syndrome after coronary intervention. However, whether thrombocytopenia also increases the bleeding risk in patients with atrial fibrillation and chronic coronary syndrome remains unclear. Methods and Results This study evaluated the AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial. Thrombocytopenia was defined as platelet count <100 000/mm 3 level at enrollment. Primary end points included incidence of major bleeding based on the International Society on Thrombosis and Hemostasis criterion and major adverse cardiovascular ischemic events (cardiac death, myocardial infarction, and stroke). A total of 2133 patients were classified into the thrombocytopenia (n=70) and nonthrombocytopenia (n=2063) groups. Major bleeding was significantly higher in the thrombocytopenia group than in the nonthrombocytopenia group (10.0% versus 4.1%, P =0.027). The thrombocytopenia group tended to have a higher risk of major adverse cardiovascular ischemic events (11.4% versus 6.2%, P =0.08). The bleeding incidence was significantly higher in patients with thrombocytopenia receiving combination therapy with rivaroxaban and a single antiplatelet drug (thrombocytopenia group, 14.3%, versus nonthrombocytopenia group, 5.0%; hazard ratio, 3.18 [95% CI, 1.27–7.97], P =0.014). Thrombocytopenia was an independent predictor of major bleeding (hazard ratio, 2.57 [95% CI, 1.19–5.56], P =0.017). Conclusions Among patients with atrial fibrillation and chronic coronary syndrome, thrombocytopenia was significantly associated with increased risk of major bleeding. Selecting drugs for patients with thrombocytopenia continuing antithrombotic therapy should be given special consideration. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02642419. https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN000016612.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3